JP2009504153A - オリゴヌクレオチド設計および/または核酸検出の方法および/または装置 - Google Patents
オリゴヌクレオチド設計および/または核酸検出の方法および/または装置 Download PDFInfo
- Publication number
- JP2009504153A JP2009504153A JP2008525967A JP2008525967A JP2009504153A JP 2009504153 A JP2009504153 A JP 2009504153A JP 2008525967 A JP2008525967 A JP 2008525967A JP 2008525967 A JP2008525967 A JP 2008525967A JP 2009504153 A JP2009504153 A JP 2009504153A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- target nucleic
- probe
- oligonucleotide
- probes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 301
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 300
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 300
- 238000000034 method Methods 0.000 title claims abstract description 167
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 112
- 238000001514 detection method Methods 0.000 title claims abstract description 97
- 238000013461 design Methods 0.000 title claims description 55
- 239000000523 sample Substances 0.000 claims abstract description 487
- 244000052769 pathogen Species 0.000 claims abstract description 119
- 230000003321 amplification Effects 0.000 claims abstract description 109
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 109
- 239000012472 biological sample Substances 0.000 claims abstract description 99
- 241000700605 Viruses Species 0.000 claims abstract description 98
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 87
- 238000002493 microarray Methods 0.000 claims abstract description 81
- 238000009826 distribution Methods 0.000 claims description 87
- 238000009396 hybridization Methods 0.000 claims description 66
- 230000002441 reversible effect Effects 0.000 claims description 51
- 238000012360 testing method Methods 0.000 claims description 37
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 35
- 239000002751 oligonucleotide probe Substances 0.000 claims description 35
- 238000003757 reverse transcription PCR Methods 0.000 claims description 35
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 30
- 238000012353 t test Methods 0.000 claims description 30
- 238000000692 Student's t-test Methods 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 230000001186 cumulative effect Effects 0.000 claims description 17
- 238000005315 distribution function Methods 0.000 claims description 17
- 244000045947 parasite Species 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 11
- 238000000767 Anderson–Darling test Methods 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 2
- 239000013615 primer Substances 0.000 claims 34
- 239000003155 DNA primer Substances 0.000 claims 1
- 239000002987 primer (paints) Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 description 40
- 238000002474 experimental method Methods 0.000 description 31
- 238000004422 calculation algorithm Methods 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 230000027455 binding Effects 0.000 description 15
- 238000010839 reverse transcription Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 208000001490 Dengue Diseases 0.000 description 12
- 206010012310 Dengue fever Diseases 0.000 description 12
- 208000025729 dengue disease Diseases 0.000 description 12
- 241000711573 Coronaviridae Species 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000013610 patient sample Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000000018 DNA microarray Methods 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000012568 clinical material Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 241000709661 Enterovirus Species 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241001428935 Human coronavirus OC43 Species 0.000 description 3
- 241000342334 Human metapneumovirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000351643 Metapneumovirus Species 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000408529 Libra Species 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000034188 Stiff person spectrum disease Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229920010524 Syndiotactic polystyrene Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000012112 ischiocoxopodopatellar syndrome Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002490 spark plasma sintering Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/202,023 US20070042388A1 (en) | 2005-08-12 | 2005-08-12 | Method of probe design and/or of nucleic acids detection |
| PCT/SG2006/000224 WO2007021250A2 (en) | 2005-08-12 | 2006-08-08 | Method and/or apparatus of oligonucleotide design and/or nucleic acid detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504153A true JP2009504153A (ja) | 2009-02-05 |
| JP2009504153A5 JP2009504153A5 (enExample) | 2009-09-24 |
Family
ID=37757981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525967A Pending JP2009504153A (ja) | 2005-08-12 | 2006-08-08 | オリゴヌクレオチド設計および/または核酸検出の方法および/または装置 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20070042388A1 (enExample) |
| EP (1) | EP1922418A4 (enExample) |
| JP (1) | JP2009504153A (enExample) |
| KR (1) | KR20080052585A (enExample) |
| CN (1) | CN101292044B (enExample) |
| AU (1) | AU2006280489B2 (enExample) |
| WO (1) | WO2007021250A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006246888A (ja) * | 2005-03-08 | 2006-09-21 | Samsung Electronics Co Ltd | プライマー−プローブセットを設計する方法、それによって設計されたプライマー−プローブセット、該セットを含むキット、該方法をコンピュータに実行させるプログラムを記録したコンピュータ読み取り可能な記録媒体、および該セットを利用した標的配列の同定方法 |
| WO2019117192A1 (ja) * | 2017-12-15 | 2019-06-20 | 東洋鋼鈑株式会社 | 一塩基多型検出用プローブの設計方法及びプローブセット |
| JP2020503067A (ja) * | 2017-02-07 | 2020-01-30 | ティーシーエム バイオテック インターナショナル コーポレーション | 癌の検出用のプローブの組合せ |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070042388A1 (en) * | 2005-08-12 | 2007-02-22 | Wong Christopher W | Method of probe design and/or of nucleic acids detection |
| US20100159533A1 (en) * | 2008-11-24 | 2010-06-24 | Helicos Biosciences Corporation | Simplified sample preparation for rna analysis |
| WO2011046614A2 (en) * | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods and systems for phylogenetic analysis |
| US20110152109A1 (en) * | 2009-12-21 | 2011-06-23 | Gardner Shea N | Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes |
| US20140163896A1 (en) * | 2011-06-16 | 2014-06-12 | University Of Rochester | Hiv incidence assays with high sensitivity and specificity |
| ES2711156T3 (es) * | 2012-05-08 | 2019-04-30 | Adaptive Biotechnologies Corp | Método para medir y calibrar el sesgo de amplificación en reacciones de PCR multiplexadas |
| CN105780129B (zh) * | 2014-12-15 | 2019-06-11 | 天津华大基因科技有限公司 | 目标区域测序文库构建方法 |
| US10787699B2 (en) * | 2017-02-08 | 2020-09-29 | Microsoft Technology Licensing, Llc | Generating pluralities of primer and payload designs for retrieval of stored nucleotides |
| CN109097450B (zh) * | 2018-08-30 | 2022-05-13 | 江苏省疾病预防控制中心 | 一种核酸序列非依赖的全rna扩增方法 |
| KR102020614B1 (ko) * | 2018-09-11 | 2019-09-11 | 한국과학기술정보연구원 | 결핵 진단용 프라이머 세트 및 이의 용도 |
| WO2020054906A1 (ko) * | 2018-09-11 | 2020-03-19 | 한국과학기술정보연구원 | 목표 유전자를 검출하기 위한 프라이머의 설계 방법 |
| CN115101128B (zh) * | 2022-06-29 | 2023-09-15 | 纳昂达(南京)生物科技有限公司 | 一种杂交捕获探针脱靶危险性评估的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000194554A (ja) * | 1998-12-25 | 2000-07-14 | Nec Corp | 演算処理装置 |
| WO2004017068A1 (ja) * | 2002-08-12 | 2004-02-26 | Hitachi High-Technologies Corporation | Dnaマイクロアレイを用いた核酸検出方法及び核酸検出装置 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030096986A1 (en) * | 2001-10-25 | 2003-05-22 | Affymetrix, Incorporated | Methods and computer software products for selecting nucleic acid probes |
| GB2377017A (en) * | 2001-06-28 | 2002-12-31 | Animal Health Inst | Detection of foot and mouth disease virus |
| US20040259124A1 (en) * | 2003-02-19 | 2004-12-23 | Affymetrix, Inc. | Methods for oligonucleotide probe design |
| US20070042388A1 (en) * | 2005-08-12 | 2007-02-22 | Wong Christopher W | Method of probe design and/or of nucleic acids detection |
-
2005
- 2005-08-12 US US11/202,023 patent/US20070042388A1/en not_active Abandoned
-
2006
- 2006-08-08 CN CN2006800369768A patent/CN101292044B/zh not_active Expired - Fee Related
- 2006-08-08 AU AU2006280489A patent/AU2006280489B2/en not_active Ceased
- 2006-08-08 KR KR1020087006089A patent/KR20080052585A/ko not_active Ceased
- 2006-08-08 EP EP06769707A patent/EP1922418A4/en not_active Withdrawn
- 2006-08-08 US US11/990,290 patent/US8234079B2/en not_active Expired - Fee Related
- 2006-08-08 JP JP2008525967A patent/JP2009504153A/ja active Pending
- 2006-08-08 WO PCT/SG2006/000224 patent/WO2007021250A2/en not_active Ceased
-
2012
- 2012-07-13 US US13/549,032 patent/US20120309643A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000194554A (ja) * | 1998-12-25 | 2000-07-14 | Nec Corp | 演算処理装置 |
| WO2004017068A1 (ja) * | 2002-08-12 | 2004-02-26 | Hitachi High-Technologies Corporation | Dnaマイクロアレイを用いた核酸検出方法及び核酸検出装置 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6012063253; Proc. IEEE Comput. Soc. Bioinform. Conf. vol.2, 2003, pp.65-74 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006246888A (ja) * | 2005-03-08 | 2006-09-21 | Samsung Electronics Co Ltd | プライマー−プローブセットを設計する方法、それによって設計されたプライマー−プローブセット、該セットを含むキット、該方法をコンピュータに実行させるプログラムを記録したコンピュータ読み取り可能な記録媒体、および該セットを利用した標的配列の同定方法 |
| JP2020503067A (ja) * | 2017-02-07 | 2020-01-30 | ティーシーエム バイオテック インターナショナル コーポレーション | 癌の検出用のプローブの組合せ |
| US11319602B2 (en) | 2017-02-07 | 2022-05-03 | Tcm Biotech Internationl Corp. | Probe combination for detection of cancer |
| WO2019117192A1 (ja) * | 2017-12-15 | 2019-06-20 | 東洋鋼鈑株式会社 | 一塩基多型検出用プローブの設計方法及びプローブセット |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090053708A1 (en) | 2009-02-26 |
| CN101292044A (zh) | 2008-10-22 |
| AU2006280489B2 (en) | 2012-05-24 |
| AU2006280489A1 (en) | 2007-02-22 |
| KR20080052585A (ko) | 2008-06-11 |
| CN101292044B (zh) | 2012-11-07 |
| US8234079B2 (en) | 2012-07-31 |
| WO2007021250A3 (en) | 2007-07-05 |
| WO2007021250A2 (en) | 2007-02-22 |
| EP1922418A2 (en) | 2008-05-21 |
| US20070042388A1 (en) | 2007-02-22 |
| US20120309643A1 (en) | 2012-12-06 |
| EP1922418A4 (en) | 2010-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8232058B2 (en) | Multiplex detection of respiratory pathogens | |
| US20120309643A1 (en) | Method and/or apparatus of oligonucleotide design and/or nucleic acid detection | |
| CN104017908B (zh) | 人乳头状瘤病毒的快速基因型鉴定分析及其装置 | |
| Wong et al. | Optimization and clinical validation of a pathogen detection microarray | |
| Laine et al. | SARS‐CoV‐2 variant with mutations in N gene affecting detection by widely used PCR primers | |
| Létant et al. | Multiplexed reverse transcriptase PCR assay for identification of viral respiratory pathogens at the point of care | |
| US20080228406A1 (en) | System and method for fungal identification | |
| US20050136395A1 (en) | Methods for genetic analysis of SARS virus | |
| JP2023519919A (ja) | 病原体を検出するためのアッセイ | |
| US20090246754A1 (en) | Optimized probes and primers and methods of using same for the detection and quantitation of bk virus | |
| AU2006259666B2 (en) | Multiplexed polymerase chain reaction for genetic sequence analysis | |
| US20090258342A1 (en) | Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1 | |
| JP2011239708A (ja) | 核酸標準物質検出用プローブの設計方法、核酸標準物質検出用プローブ及び当該核酸標準物質検出用プローブを有する核酸検出系 | |
| US20110014598A1 (en) | Optimized probes and primers and method of using same for the detection of herpes simplex virus | |
| Jabado et al. | Nonparametric methods for the analysis of single-color pathogen microarrays | |
| US20110256537A1 (en) | Optimized oligonucleotides and methods of using same for the screening, detection, isolation, quantitation, monitoring and sequencing of prostate cancer associated viruses and host biomarkers | |
| HK1201567B (en) | Rapid genotyping analysis for human papillomavirus and the device thereof | |
| JP2009509499A (ja) | 遺伝子配列分析のための多重ポリメラーゼ連鎖反応 | |
| HK1183063A (en) | Rapid genotyping analysis for human papillomavirus and the device thereof | |
| HK1183063B (en) | Rapid genotyping analysis for human papillomavirus and the device thereof | |
| HK1202136B (en) | Rapid genotyping analysis for human papillomavirus and the device thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090807 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090807 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120309 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130423 |